Clinical Trials in Thalassemia Cell and Gene Therapy Application
Cooley's Anemia Foundation funds clinical trials in cell and gene therapy to advance curative treatments for Thalassemia, supporting essential scientific and trial-related research activities.
Funder: Cooley's Anemia Foundation
Due Dates (Anticipated): December 2026 (Letter of Intent) | February 2027 (Full application)
Funding Amounts: Up to $75,000/year (including up to 8% indirect costs); renewable for a second year with satisfactory progress.
Summary: Supports national and international clinical trials in cell and gene therapy to advance cures for Thalassemia, covering key trial-related costs.
Description
This grant supports clinical trials in cell and gene therapy aimed at advancing curative strategies for Thalassemia. The program is open to both national and international investigators and funds phase I (safety) and phase II (efficacy) trials. Funding is intended to help launch or conduct clinical trials, covering essential trial-related costs such as clinical-grade vector production, subject assessments, and laboratory studies directly related to the trial. The foundation emphasizes a realistic timeline toward human trials and requires a thorough justification of resource allocation and documentation of other project support. The initiative reflects the foundation’s commitment to accelerating transformative therapies for Thalassemia.
